First Eagle Investment Management
IOVA icon

First Eagle Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

First Eagle Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-150,000
Closed -$1.04M – 330
2016
Q4 		$1.04M Hold
150,000
– – ﹤0.01% 216
2016
Q3 		$1.24M Hold
150,000
– – ﹤0.01% 236
2016
Q2 		$1.22M Buy
+150,000
New +$942K ﹤0.01% 243

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Eagle Investment Management's IOVA Position: Q1 2017 in Review

First Eagle Investment Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2017, closing a stake of 150,000 shares — an estimated $1.04M sold.

First Eagle Investment Management first reported a position in IOVA in Q2 2016 and held it in 3 quarters. The position peaked at $1.24M in Q3 2016. 81 funds tracked by Wall St. Rank hold IOVA as of Q1 2017.

  • First Eagle Investment Management reported no remaining Iovance Biotherapeutics position as of Q1 2017 after selling out during the quarter.
  • First Eagle Investment Management sold 150,000 Iovance Biotherapeutics shares in Q1 2017, an estimated $1.04M.
  • First Eagle Investment Management first reported a position in Iovance Biotherapeutics in Q2 2016 and held it in 3 quarters.
  • First Eagle Investment Management's Iovance Biotherapeutics position peaked at $1.24M in Q3 2016.
  • 81 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2017.

Based on First Eagle Investment Management's 13F filing for Q1 2017, filed 5 May 2017.